Hypertension and Diabetic Nephropathy

L. Kihm

doi:10.1055/s-0036-1582341

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2016; 124(07): e1-e2
DOI: 10.1055/s-0036-1582341

Editorial

Hypertension and Diabetic Nephropathy

L. Kihm

¹Department of Internal Medicine I and Clinical Chemistry, University of Heidelberg

› Author Affiliations

Abstract

Full Text

References

References
1 Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. NEJM 1993; 329: 1456-1462
2 James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama 2014; 311: 507-520
3 Group SR. Wright Jr JT, Williamson JD, Whelton KM et al. A randomized trial of intensive vs. standard blood-pressure control. NEJM 2015; 373: 2103-2116
4 Group AS. Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. NEJM 2010; 362: 1575-1585
5 Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387: 435-443
6 Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-967
7 Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 352: i717
8 Stanton RC. Diabetic kidney disease and hypertension. Exp Clin Endocrinol Diab 2016; 124: 93-98
9 Brito R, Castillo G, Gonzalez J et al. Oxidative stress in hypertension: mechanisms and therapeutic opportunities. Exp Clin Endocrinol Diab 2015; 123: 325-335
10 Guclu A, Erdur FM, Turkmen K. The emerging role of sirtuin 1 in cellular metabolism, diabetes mellitus, diabetic kidney disease and hypertension. Exp Clin Endocrinol Diab 2016; 124: 131-139
11 Bolignano D, Pisano A, Coppolino G. The dark side of blocking ras in diabetic patients with incipient or manifested nephropathy. Exp Clin Endocrinol Diab 2016; 350-360
12 Grolla E, Bonanni L, Cutolo A et al. Disputes in the treatment of diabetic nephropathy: the dual blockade of renin-angiotensin system. Exp Clin Endocrinol Diab 2016; 361-366
13 Williams B, MacDonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-2068
14 Cramer H. The efficacy and safety of yoga in managing hypertension. Exp Clin Endocrinol Diab 2016; 124: 65-70
15 Kuhl C, Frey N, Frank D. Recent developments and controversies in the treatment of resistant hypertension. Exp Clin Endocrinol Diab 2016; 124: 178-186
16 Asbach E, Williams TA, Reincke M. Recent developments in primary aldosteronism. Exp Clin Endocrinol Diab 2016; 124: 335-341
17 Kihm MC, Vogel B, Zeier M et al. Renal artery stenosis – are there patients who benefit from intervention?. Exp Clin Endocrinol Diab 2016; 342-349